Asia-Pacific: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Asia-Pacific

The Asia-Pacific prophylactic medicaments containing insulin market rose remarkably to $X in 2022, picking up by 5.7% against the previous year. Overall, consumption showed a resilient increase. The level of consumption peaked at $X in 2020; however, from 2021 to 2022, consumption failed to regain momentum.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Asia-Pacific

In value terms, prophylactic medicaments containing insulin production totaled $X in 2022 estimated in export price. Over the period under review, production posted a buoyant expansion. The most prominent rate of growth was recorded in 2013 when the production volume increased by 39% against the previous year. Over the period under review, production reached the peak level at $X in 2020; however, from 2021 to 2022, production remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in Asia-Pacific

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses increased by 3.9% to X tons, rising for the second year in a row after seven years of decline. Overall, exports, however, continue to indicate a relatively flat trend pattern. The growth pace was the most rapid in 2013 with an increase of 83% against the previous year. As a result, the exports reached the peak of X tons. From 2014 to 2022, the growth of the exports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin exports declined dramatically to $X in 2022. In general, exports posted a significant increase. The most prominent rate of growth was recorded in 2021 when exports increased by 106%. As a result, the exports reached the peak of $X, and then fell rapidly in the following year.

Exports by Country

India (X tons) and China (X tons) dominates exports structure, together committing 87% of total exports. It was distantly followed by Malaysia (X tons), achieving a 6.3% share of total exports. Singapore (X tons) held a relatively small share of total exports.

From 2012 to 2022, the most notable rate of growth in terms of shipments, amongst the leading exporting countries, was attained by Singapore (with a CAGR of +173.5%), while the other leaders experienced more modest paces of growth.

In value terms, China ($X) remains the largest prophylactic medicaments containing insulin supplier in Asia-Pacific, comprising 79% of total exports. The second position in the ranking was held by India ($X), with a 9.6% share of total exports. It was followed by Malaysia, with a 6.5% share.

In China, prophylactic medicaments containing insulin exports expanded at an average annual rate of +50.7% over the period from 2012-2022. In the other countries, the average annual rates were as follows: India (-1.6% per year) and Malaysia (+39.2% per year).

Export Prices by Country

The export price in Asia-Pacific stood at $X per ton in 2022, dropping by -20.7% against the previous year. Overall, the export price, however, posted a significant increase. The most prominent rate of growth was recorded in 2015 an increase of 73%. The level of export peaked at $X per ton in 2021, and then fell notably in the following year.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was China ($X per ton), while India ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by India (+5.2%), while the other leaders experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in Asia-Pacific

In 2022, supplies from abroad of medicaments containing insulin but not antibiotics in measured doses decreased by -12.2% to X tons, falling for the second consecutive year after three years of growth. The total import volume increased at an average annual rate of +2.2% over the period from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded in certain years. The most prominent rate of growth was recorded in 2016 with an increase of 15%. The volume of import peaked at X tons in 2020; however, from 2021 to 2022, imports remained at a lower figure.

In value terms, prophylactic medicaments containing insulin imports fell remarkably to $X in 2022. In general, imports showed a slight setback. The pace of growth was the most pronounced in 2016 with an increase of 12%. Over the period under review, imports hit record highs at $X in 2021, and then declined significantly in the following year.

Imports by Country

The purchases of the five major importers of medicaments containing insulin but not antibiotics in measured doses, namely Japan, China, Pakistan, South Korea and Australia, represented more than half of total import. It was distantly followed by Indonesia (X tons), comprising a 4.6% share of total imports. Thailand (X tons), India (X tons), the Philippines (X tons), Vietnam (X tons), Singapore (X tons), New Zealand (X tons) and Taiwan (Chinese) (X tons) followed a long way behind the leaders.

From 2012 to 2022, the biggest increases were recorded for India (with a CAGR of +34.1%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, Japan ($X), China ($X) and India ($X) were the countries with the highest levels of imports in 2022, with a combined 55% share of total imports. Australia, South Korea, Pakistan, Vietnam, Indonesia, Singapore, the Philippines, Thailand, New Zealand and Taiwan (Chinese) lagged somewhat behind, together comprising a further 40%.

Singapore, with a CAGR of +29.9%, recorded the highest rates of growth with regard to the value of imports, in terms of the main importing countries over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The import price in Asia-Pacific stood at $X per ton in 2022, waning by -17.8% against the previous year. Overall, the import price continues to indicate a perceptible curtailment. The most prominent rate of growth was recorded in 2021 when the import price increased by 11% against the previous year. The level of import peaked at $X per ton in 2012; however, from 2013 to 2022, import prices remained at a lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was India ($X per ton), while Pakistan ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Pakistan (+14.6%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :